Q32 Bio Inc. (QTTB)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
8.00 USD
-0.74
(-8.467%) ⇩
(Oct. 13, 2026, 1:37 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:27 a.m. EDT
The long-term investment case is severely compromised by a catastrophic multi-year decline; the stock has lost 99% of its value over the last seven years, with six of those years seeing negative returns. Despite a recent surge in price, the underlying business shows no signs of recovery, evidenced by negative forward earnings estimates and a massive drop in revenue per share compared to historical peaks. The balance sheet, while currently showing low debt, is likely propped up by the recent $200 million public offering, which often signals distress financing rather than organic strength. The short-term outlook remains cautious; although the stock recently rallied, the options chain reveals significant hedging activity via put buying, indicating that traders expect volatility and potential further drops. The statistical forecasting model offers virtually no guidance due to extremely low reliability, reinforcing the need to rely on the stark fundamental reality: this is a deep-value trap with deteriorating fundamentals, not a turnaround story. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.148822 |
| AutoARIMA | 0.149439 |
| MSTL | 0.163395 |
| AutoTheta | 0.218261 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 134.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.049 |
| Excess Kurtosis | -0.88 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.001 |
| Revenue per Share | 3.622 |
| Market Cap | 238,155,728 |
| Trailing P/E | 2.54 |
| Forward P/E | -7.84 |
| Beta | -0.11 |
| Profit Margins | 62.87% |
| Website | https://www.q32bio.com |
As of Oct. 10, 2026, 6:27 a.m. EDT: Speculators are positioning defensively with heavy put volume relative to calls, particularly in the January 2027 expiration where in-the-money puts dominate open interest. While there is some call activity at higher strikes ($15-$20), the overwhelming open interest concentration is in out-of-the-money puts, suggesting a fear of further downside rather than a bullish breakout.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2583978 |
| Address1 | 830 Winter Street |
| All Time High | 572.4 |
| All Time Low | 1.345 |
| Ask | 10.27 |
| Ask Size | 2 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,594,750 |
| Average Daily Volume3 Month | 914,275 |
| Average Volume | 914,275 |
| Average Volume10Days | 1,594,750 |
| Beta | -0.109 |
| Bid | 6.12 |
| Bid Size | 2 |
| Book Value | 4.462 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.0 |
| Current Ratio | 20.301 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 8.69 |
| Day Low | 7.97 |
| Debt To Equity | 5.001 |
| Display Name | Q32 Bio |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,762,432,200 |
| Earnings Timestamp Start | 1,762,432,200 |
| Ebitda | 21,818,000 |
| Ebitda Margins | 0.40601003 |
| Enterprise To Ebitda | 7.297 |
| Enterprise To Revenue | 2.963 |
| Enterprise Value | 159,211,136 |
| Eps Forward | -1.02 |
| Eps Trailing Twelve Months | 3.15 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.4798 |
| Fifty Day Average Change | -4.4798 |
| Fifty Day Average Change Percent | -0.3589641 |
| Fifty Two Week Change Percent | 125.83978 |
| Fifty Two Week High | 23.57 |
| Fifty Two Week High Change | -15.57 |
| Fifty Two Week High Change Percent | -0.66058546 |
| Fifty Two Week Low | 1.905 |
| Fifty Two Week Low Change | 6.0950003 |
| Fifty Two Week Low Change Percent | 3.1994753 |
| Fifty Two Week Range | 1.905 - 23.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,522,243,800,000 |
| Float Shares | 12,732,698 |
| Forward Eps | -1.02 |
| Forward P E | -7.8431373 |
| Free Cashflow | 19,392,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Fullday Change | -0.7399998 |
| Fullday Change Percent | -8.466817 |
| Fullday Price | 8.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.73301005 |
| Gross Profits | 39,390,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02096 |
| Held Percent Institutions | 0.87728 |
| Implied Shares Outstanding | 29,769,466 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,711,411,200 |
| Last Split Factor | 1:18 |
| Long Business Summary | Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts. |
| Long Name | Q32 Bio Inc. |
| Market | us_market |
| Market Cap | 238,155,728 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_669405676 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 33,786,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 284,149,552 |
| Number Of Analyst Opinions | 6 |
| Open | 8.69 |
| Operating Cashflow | -19,828,000 |
| Operating Margins | 0.39938998 |
| Payout Ratio | 0.0 |
| Phone | 781 999 0232 |
| Previous Close | 8.74 |
| Price Hint | 2 |
| Price To Book | 1.792918 |
| Price To Sales Trailing12 Months | 4.431876 |
| Profit Margins | 0.62873 |
| Quick Ratio | 19.779 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.14286 |
| Region | US |
| Regular Market Change | -0.7399998 |
| Regular Market Change Percent | -8.466817 |
| Regular Market Day High | 8.69 |
| Regular Market Day Low | 7.97 |
| Regular Market Day Range | 7.97 - 8.69 |
| Regular Market Open | 8.69 |
| Regular Market Previous Close | 8.74 |
| Regular Market Price | 8.0 |
| Regular Market Time | 1,791,913,026 |
| Regular Market Volume | 364,020 |
| Return On Assets | 0.14741999 |
| Return On Equity | 0.72138 |
| Revenue Per Share | 3.622 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 29,769,466 |
| Shares Percent Shares Out | 0.15689999 |
| Shares Short | 4,671,943 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 3,556,186 |
| Short Name | Q32 Bio Inc. |
| Short Percent Of Float | 0.2229 |
| Short Ratio | 5.14 |
| Source Interval | 15 |
| State | MA |
| Symbol | QTTB |
| Target High Price | 59.0 |
| Target Low Price | 29.0 |
| Target Mean Price | 39.66667 |
| Target Median Price | 38.0 |
| Total Cash | 106,270,000 |
| Total Cash Per Share | 3.57 |
| Total Debt | 5,296,000 |
| Total Revenue | 53,737,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.15 |
| Trailing P E | 2.5396824 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.883425 |
| Two Hundred Day Average Change | -0.88342476 |
| Two Hundred Day Average Change Percent | -0.099446416 |
| Type Disp | Equity |
| Volume | 364,020 |
| Website | https://www.q32bio.com |
| Zip | 2,451 |